AU7935791A - Fusion proteins with immunoglobulin portions, the preparation and use thereof - Google Patents

Fusion proteins with immunoglobulin portions, the preparation and use thereof

Info

Publication number
AU7935791A
AU7935791A AU79357/91A AU7935791A AU7935791A AU 7935791 A AU7935791 A AU 7935791A AU 79357/91 A AU79357/91 A AU 79357/91A AU 7935791 A AU7935791 A AU 7935791A AU 7935791 A AU7935791 A AU 7935791A
Authority
AU
Australia
Prior art keywords
preparation
fusion proteins
immunoglobulin
protein
immunoglobulin portions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU79357/91A
Other versions
AU655421B2 (en
Inventor
Leander Lauffer
Patricia Oquendo
Brian Seed
Gerd Zettlmessl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
General Hospital Corp
Original Assignee
Sanofi Aventis Deutschland GmbH
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH, General Hospital Corp filed Critical Sanofi Aventis Deutschland GmbH
Publication of AU7935791A publication Critical patent/AU7935791A/en
Application granted granted Critical
Publication of AU655421B2 publication Critical patent/AU655421B2/en
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH, GENERAL HOSPITAL CORPORATION, THE reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH Alteration of Name(s) in Register under S187 Assignors: BEHRINGWERKE AKTIENGESELLSCHAFT, GENERAL HOSPITAL CORPORATION, THE
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A soluble fusion protein (I) comprising a human protein (II), or part of it, that is not of the immunoglobulin (Ig) family and different parts (III) of Ig molecules of any subclass, is new. An independent claim is also included for a method for preparing (I) by introducing a DNA that encodes it into a mammalian cell expression system, expressing (I), and purification by affinity chromatography through the Ig component. ACTIVITY : Hemostatic; Immunosuppressive; Antiallergic; Antianemic; Anticoagulant; Thrombolytic. No details of tests for these activities are given. MECHANISM OF ACTION : Protein substitution or inhibition.
AU79357/91A 1990-06-28 1991-06-27 Fusion proteins with immunoglobulin portions, the preparation and use thereof Expired AU655421B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4020607 1990-06-28
DE4020607 1990-06-28

Publications (2)

Publication Number Publication Date
AU7935791A true AU7935791A (en) 1992-01-02
AU655421B2 AU655421B2 (en) 1994-12-22

Family

ID=6409260

Family Applications (1)

Application Number Title Priority Date Filing Date
AU79357/91A Expired AU655421B2 (en) 1990-06-28 1991-06-27 Fusion proteins with immunoglobulin portions, the preparation and use thereof

Country Status (17)

Country Link
EP (3) EP0464533B1 (en)
JP (2) JPH05247094A (en)
KR (3) KR100249572B1 (en)
AT (2) ATE169030T1 (en)
AU (1) AU655421B2 (en)
CA (1) CA2045869C (en)
CY (2) CY2151B1 (en)
DE (3) DE59109269D1 (en)
DK (2) DK0835939T3 (en)
ES (2) ES2251009T3 (en)
GR (1) GR3027567T3 (en)
HK (2) HK1010216A1 (en)
IE (1) IE912256A1 (en)
LU (1) LU90592I2 (en)
NL (1) NL300009I2 (en)
PT (1) PT98113B (en)
UY (1) UY25897A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DK0417563T3 (en) 1989-09-12 2000-11-06 Hoffmann La Roche TNF-binding proteins
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
DE4322330A1 (en) 1992-08-31 1994-03-03 Behringwerke Ag Use of the IL-4 receptor for the therapy, prophylaxis and diagnosis of allergic, viral, parasitic and bacterial diseases as well as fungal infections
AU4382193A (en) * 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins
US6274348B1 (en) 1992-05-19 2001-08-14 Xoma Corporation Methods for the preparation of positively charged proteins
DE4228839A1 (en) * 1992-08-29 1994-03-03 Behringwerke Ag Methods for the detection and determination of mediators
CA2161971A1 (en) * 1993-04-30 1994-11-10 Randal W. Scott Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
DE4407386B4 (en) * 1994-03-05 2009-01-15 Dade Behring Marburg Gmbh Method for reactivation of purified membrane proteins by freezing
CA2165412A1 (en) * 1994-04-28 1995-10-29 Barry John Woodhams Calibrator for prothrombin time (pt) assays
WO1996004388A1 (en) * 1994-07-29 1996-02-15 Smithkline Beecham Plc Novel compounds
WO1996018412A1 (en) * 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
ES2194973T3 (en) * 1995-01-17 2003-12-01 Brigham & Womens Hospital TRANSPORTATION OF SPECIFIC TRANSEPITELIAL IMMUNOGENS OF THE RECEIVER.
DE19538716A1 (en) * 1995-10-18 1997-04-24 Behringwerke Ag Method for quantification of activated coagulation factor VII (FVIIa)
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
AU6163196A (en) * 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
DE19538715A1 (en) * 1995-10-18 1997-04-30 Behringwerke Ag Process for cleaning factor VII and activated factor VII
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
EP0961831B1 (en) 1996-08-16 2008-10-29 Human Genome Sciences, Inc. Human endokine alpha
PT963377E (en) 1996-08-30 2009-05-11 Human Genome Sciences Inc Interleukin-19
ATE302272T1 (en) 1996-10-25 2005-09-15 Human Genome Sciences Inc NEUTROKIN ALPHA
AU736876B2 (en) 1996-12-06 2001-08-02 Amgen, Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
DE69837806T3 (en) 1997-01-28 2012-01-05 Human Genome Sciences, Inc. "DEATH-DOMAIN" -INTERDENTING RECEPTOR 4 (DR4), A MEMBER OF THE TNF-RECEPTOR SUPERFAMILY, BINDING ON TRAIL (APO-2L)
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
ATE487737T1 (en) 1997-05-30 2010-11-15 Human Genome Sciences Inc 32 HUMAN SECRETED PROTEINS
WO1999002709A1 (en) * 1997-07-10 1999-01-21 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
JP2002017353A (en) * 1997-12-19 2002-01-22 Japan Tobacco Inc Method for determining denaturated ldl
NZ505499A (en) 1998-01-23 2002-07-26 Immunex Corp Accessory protein-like DNA and polypeptides
EP1093457B8 (en) 1998-03-19 2011-02-02 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
WO2000023594A1 (en) 1998-10-22 2000-04-27 The General Hospital Corporation BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
DK1141237T3 (en) 1998-12-31 2006-02-13 Gen Hospital Corp PTH receptor and screening assay using this
WO2000046380A2 (en) 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
JP3660880B2 (en) * 1999-05-07 2005-06-15 ジェネンテック・インコーポレーテッド Novel chimpanzee erythropoietin (CHEPO) polypeptide and nucleic acid encoding the same
US6362324B1 (en) 1999-06-30 2002-03-26 Millennium Pharmaceuticals, Inc. 17867 a novel human aminopeptidase
US6369210B1 (en) * 1999-06-30 2002-04-09 Millennium Pharmaceuticals, Inc. 22012, human carboxypeptidase
AU7734800A (en) 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6248353B1 (en) 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
US20030143226A1 (en) 2000-03-02 2003-07-31 Yuko Kobayashi Human monoclonal antibodies against oxidized ldl receptor and medicinal use thereof
AU2001259758A1 (en) 2000-05-12 2001-11-26 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
WO2001092340A2 (en) 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
JP4932125B2 (en) 2000-08-25 2012-05-16 ビーエーエスエフ プラント サイエンス ゲーエムベーハー Plant polynucleotides encoding novel prenyl proteases
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
EP1683865A3 (en) 2001-02-02 2006-10-25 Eli Lilly & Company Mammalian proteins and in particular CD200
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
KR100942393B1 (en) 2001-05-25 2010-02-17 휴먼 게놈 사이언시즈, 인코포레이티드 Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7364736B2 (en) 2001-06-26 2008-04-29 Amgen Inc. Antibodies to OPGL
AU2002339843B2 (en) 2001-07-23 2007-12-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
KR100453877B1 (en) 2001-07-26 2004-10-20 메덱스젠 주식회사 METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR
WO2004009775A2 (en) 2002-07-19 2004-01-29 Targacept, Inc. Methods and compositions relating to chimeric nicotinic receptor subunits
CN102174533A (en) 2002-10-15 2011-09-07 英特塞尔股份公司 Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
PT1601770E (en) 2003-03-04 2009-12-07 Intercell Ag Streptococcus pyogenes antigens
JP4334480B2 (en) 2003-03-19 2009-09-30 ザ ジェネラル ホスピタル コーポレイション A conformationally constrained parathyroid hormone using an α-helix stabilizer
CA2522238A1 (en) 2003-04-15 2004-10-28 Intercell Ag S. pneumoniae antigens
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2012203896B2 (en) * 2003-05-06 2014-09-25 Bioverativ Therapeutics Inc. Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
ES2361036T3 (en) * 2003-05-06 2011-06-13 Syntonix Pharmaceuticals, Inc. CHEMICAL PROTEINS VII-FC OF THE COAGULATION FACTOR FOR THE TREATMENT OF A HEMOSTATIC DISORDER.
EP2287177A3 (en) 2003-05-07 2011-08-31 Intercell AG Streptococcus agalactiae antigens I + II
EP2327720A1 (en) 2003-05-30 2011-06-01 Intercell AG Enterococcus antigens
WO2005009358A2 (en) 2003-07-17 2005-02-03 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
DK2256134T3 (en) 2003-11-13 2014-02-24 Hanmi Science Co Ltd IgG Fc fragment to a drug carrier and process for preparation thereof
AU2005238464B2 (en) 2004-04-22 2011-01-27 Grifols Therapeutics Inc. Recombinantly modified plasmin
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
EP2287310B1 (en) 2004-07-22 2015-05-06 Five Prime Therapeutics, Inc. Compositions and methods using MGD-CSF in disease treatment
EP1797096B1 (en) 2004-09-06 2011-07-27 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines as inhibitors of protein kinase b (akt)
CN101072793B (en) * 2004-12-09 2012-06-20 默克专利有限公司 Il-7 variants with reduced immunogenicity
JP2008538494A (en) 2005-04-07 2008-10-30 ザ クリーブランド クリニック ファウンデーション Gamma retroviruses associated with cancer
KR100754667B1 (en) 2005-04-08 2007-09-03 한미약품 주식회사 Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same
WO2007021129A1 (en) 2005-08-16 2007-02-22 Hanmi Pharmaceutical Co., Ltd. A method for the mass production of immunoglobulin fc region deleted initial methionine residues
EP1931384A4 (en) 2005-09-09 2010-03-10 Univ Johns Hopkins Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
EP1933873A4 (en) 2005-10-13 2009-12-02 Human Genome Sciences Inc Methods and compositions for use in treatment of patients with autoantibody positive diseases
CA2628238A1 (en) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
EP1785434A1 (en) 2005-11-11 2007-05-16 Ludwig-Maximilians-Universität München Targeting and tracing of antigens in living cells
DK2671954T3 (en) 2006-01-20 2018-08-13 Cell Signaling Technology Inc Translocation and mutant ROS kinase in human non-small cell lung carcinoma
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
JP5337691B2 (en) 2006-04-20 2013-11-06 ベクトン・ディキンソン・アンド・カンパニー Thermostable protein and method for producing and using the same
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US8143374B2 (en) 2006-08-04 2012-03-27 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
EP2275434A1 (en) 2006-09-15 2011-01-19 Intercell AG Borrelia antigens
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
KR100888022B1 (en) 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 Fusion Proteion of Imunoglobulin Fc and Human Apolipoproteina Kringle Fragment
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
JP2010532657A (en) 2007-05-02 2010-10-14 インターセル アーゲー Klebsiella antigens
AU2008265218A1 (en) 2007-06-18 2008-12-24 Intercell Ag Chlamydia antigens
WO2009012600A1 (en) 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins
EP2187902B1 (en) 2007-08-01 2013-04-17 The General Hospital Corporation Screening methods using g-protein coupled receptors and related compositions
NZ584642A (en) 2007-09-27 2012-08-31 Japan Tobacco Inc Factor involved in latent infection with herpesvirus, and use thereof
AU2008314567B2 (en) 2007-10-18 2014-11-20 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
EP3181588A1 (en) 2008-01-11 2017-06-21 Adheron Therapeutics, Inc. Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders
EP2274437B1 (en) 2008-04-10 2015-12-23 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
US8617863B2 (en) 2008-06-04 2013-12-31 Grifols Therapeutics Inc. Composition, method, and kit for preparing plasmin
RU2483081C2 (en) 2008-07-23 2013-05-27 Ханми Сайенс Ко.,Лтд.,Kr Polypeptide complex containing non-peptidyl polymer, having three functional ends
DK2881402T3 (en) 2009-02-12 2017-08-28 Cell Signaling Technology Inc Mutant ROS expression in human liver cancer
EP2405938A2 (en) 2009-02-13 2012-01-18 Intercell AG Nontypable haemophilus influenzae antigens
PT2403865E (en) 2009-03-03 2015-11-18 Grifols Therapeutics Inc Methods for preparing plasminogen
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
HUE035618T2 (en) 2010-01-15 2018-05-28 Kirin Amgen Inc Antibody formulation and therapeutic regimens
EP2525808A2 (en) 2010-01-19 2012-11-28 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
AU2011248184B2 (en) 2010-05-04 2015-12-17 Board Of Regents, The University Of Texas System Detection and treatment of fibrosis
WO2011143406A2 (en) 2010-05-13 2011-11-17 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
CN103153331B (en) 2010-07-15 2017-03-22 亚德赫伦医疗公司 Humanized antibodies targeting the EC1 domain of cadherin-11 and related compositions and methods
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US20150064163A1 (en) 2011-09-02 2015-03-05 Lifenet Health BMP Peptides & Methods of Use
US9290564B2 (en) 2012-05-24 2016-03-22 Mountgate Group Limited Compositions and methods related to the prevention and treatment of rabies infection
EP2685260A1 (en) 2012-07-09 2014-01-15 Ludwig-Maximilians-Universität München Direct and quantitative detection of targets in living cells
KR101609840B1 (en) * 2012-07-12 2016-04-07 한국생명공학연구원 Adsorbent columns using antibody Fcbinding peptide
PE20150996A1 (en) 2012-09-11 2015-08-01 Coherus Biosciences Inc PROPERLY FOLDED ETANERCEPT FOR HIGH PURITY AND EXCELLENT PERFORMANCE
KR102073748B1 (en) 2013-01-31 2020-02-05 한미약품 주식회사 Recombinant yeast transformant and process for preparing immunoglobulin Fc fragment employing the same
WO2014152497A2 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
AR096891A1 (en) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME
ES2760002T3 (en) 2014-03-31 2020-05-12 Amgen K A Inc Methods of treating nail and scalp psoriasis
US20170246259A1 (en) 2014-09-10 2017-08-31 Georgetown University Compositions and Methods of Using Interleukin-4 Induced Gene 1 (IL-4I1)
JP7175608B2 (en) 2014-11-19 2022-11-21 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク Osteocalcin as a treatment for age-related frailty
WO2016149139A1 (en) 2015-03-13 2016-09-22 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
CN111587123A (en) 2017-11-09 2020-08-25 品通治疗有限公司 Methods and compositions for generating and using humanized conformation-specific phosphorylated tau antibodies
US20210277118A1 (en) 2018-06-21 2021-09-09 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
JP2024503657A (en) 2021-01-13 2024-01-26 メモリアル スローン－ケタリング キャンサー センター Antibody-pyrrolobenzodiazepine derivative conjugate
KR20230146522A (en) 2021-01-13 2023-10-19 메모리얼 슬로안 케터링 캔서 센터 Anti-DLL3 antibody-drug conjugate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269455A3 (en) * 1986-11-28 1989-09-06 Takeda Chemical Industries, Ltd. Highly purified fused protein comprising human ige fc fragment and production thereof
ZA89430B (en) * 1988-01-22 1989-10-25 Gen Hospital Corp Cloned genes encoding ig-cd4 fusion proteins and the use thereof
AU648041B2 (en) * 1989-08-23 1994-04-14 General Hospital Corporation, The Non-human primate CD4 polypeptides, fusions thereof, DNA encoding, and uses thereof
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DK0417563T3 (en) * 1989-09-12 2000-11-06 Hoffmann La Roche TNF-binding proteins
JPH09506761A (en) * 1990-11-09 1997-07-08 ステファン ディー．ギリーズ Immune complex of cytokines
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity

Also Published As

Publication number Publication date
JP3768427B2 (en) 2006-04-19
EP0835939A3 (en) 1998-04-22
JPH05247094A (en) 1993-09-24
DE10075010I1 (en) 2003-06-12
CY2151B1 (en) 2002-08-23
EP1586635A1 (en) 2005-10-19
DK0835939T3 (en) 2006-03-13
NL300009I1 (en) 2000-08-01
CA2045869A1 (en) 1991-12-29
JP2002201200A (en) 2002-07-16
KR100280070B1 (en) 2001-01-15
UY25897A1 (en) 2001-01-31
DK0464533T3 (en) 1999-04-26
ES2251009T3 (en) 2006-04-16
PT98113B (en) 1998-12-31
DE10075010I2 (en) 2004-01-29
EP0464533B1 (en) 1998-07-29
CA2045869C (en) 2009-01-27
CY2000009I1 (en) 2016-10-05
EP0835939B1 (en) 2005-11-09
EP0464533A1 (en) 1992-01-08
KR920000789A (en) 1992-01-29
ES2120949T3 (en) 1998-11-16
PT98113A (en) 1992-05-29
ES2120949T4 (en) 2011-12-29
HK1012015A1 (en) 1999-07-23
AU655421B2 (en) 1994-12-22
ATE169030T1 (en) 1998-08-15
LU90592I2 (en) 2000-07-31
GR3027567T3 (en) 1998-11-30
KR100280069B1 (en) 2001-01-15
DE59109269D1 (en) 2005-12-15
ATE309376T1 (en) 2005-11-15
HK1010216A1 (en) 1999-06-17
EP0835939B8 (en) 2006-01-11
EP0835939A2 (en) 1998-04-15
DE59109032D1 (en) 1998-09-03
KR100249572B1 (en) 2000-03-15
IE912256A1 (en) 1992-01-01
NL300009I2 (en) 2000-12-01

Similar Documents

Publication Publication Date Title
AU7935791A (en) Fusion proteins with immunoglobulin portions, the preparation and use thereof
Thomas et al. Brain fibroblast growth factor: nonidentity with myelin basic protein fragments.
AU7575487A (en) Method for the preparation of proteins with factor VIII activity by microbial host cells; expression, vectors, host cells, antibodies
GR3029740T3 (en) Fragments of prion proteins.
CA2144223A1 (en) Effector proteins of rapamycin
MY102472A (en) Preparation of funtional human urokinase proteins.
HK129394A (en) Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
ATE44768T1 (en) PROCESS FOR THE MICROBIOLOGICAL PREPARATION OF HUMAN SERUM ALBUMIN.
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
WO1999003993A3 (en) Suppressors of cytokine signaling; related reagents
WO1998023750A3 (en) Mammalian chemokines
PT733104E (en) PURIFICATION OF VITAMIN K DEPENDENT PROTEINS BY MEMBRANE CHROMATOGRAPHY
Rapoport Intracellular compartmentation and secretion of carp proinsulin synthesized in Xenopus oocytes
AU2459188A (en) Anticoagulative protein pp4-x, and its preparation and use
WO2000017363A3 (en) Interleukin-1 like molecule: interleukin-1-zeta; nucleic acids, polypeptides, antibodies, their uses
ATE134218T1 (en) METHOD FOR PURIFYING RECOMBINANT T-PA FROM THEIR CORRESPONDING HOST CELL PROTEINS
MX9700255A (en) METHOD FOR IDENTIFYING NUCLEIC ACIDS ENCODING c-fos PROMOTER ACTIVATING PROTEINS.
IE871932L (en) Method for the preparation of proteins with factor viii¹activity by microbial host cells, expression vectors, host¹cells, antibodies
ZA875267B (en) Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
AU6992496A (en) Circular DNA molecule with conditional origin of replication, method for preparing same and use thereof in gene therapy
FI934079A (en) Method for preparing a fusion protein
DK318086A (en) PREPARATION FOR THE TREATMENT OF HAEMOFILI A INHIBITOR PATIENTS AND PROCEDURE FOR THE PREPARATION OF SUCH PREPARATION